The first batch of the drug developed by the Defence Research and Development Organisation (DRDO) to treat moderate to severe Covid-19 patients was launched on Monday (17 May).
Minister of Defence Rajnath Singh and Minister of Health and Family Welfare, Dr Harsh Vardhan jointly launched the new COVID drug 2-DG at DRDO Bhawan.
The anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, along with Dr Reddy’s Laboratories (DRL), Hyderabad, the Defence Ministry said in a statement.
The 2-DG has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.
It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.
An appeal from Swarajya
At Swarajya, we rely on our readers' support through subscriptions to sustain our media platform. Unlike larger conglomerates, we are unable to relentlessly chase advertising money — our model is largely built on your patronage.
Your support has never been more crucial. We work tirelessly to deliver 10-15 high-quality articles daily, ensuring you receive insightful content from 7 AM to 10 PM.
If you believe India's story has to be articulated in a way it has never been done before without shrugging it off, become a patron (or) subscribe now for ₹̶2̶4̶0̶0̶ ₹1999 and get 12 print issues, unlimited digital access for 1 year, a special India that is Bharat T-shirt (Offer ends soon).
We are counting on you!